We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Dramatic Growth Predicted for Global POC Testing Segment

By LabMedica International staff writers
Posted on 19 Oct 2009
The global point-of-care (POC) testing market will experience striking growth from US$12.8 billion in 2008 to $17.8 billion by 2014 according to a new report.

Distributed by Life Science Intelligence (LSI; Huntington Beach, CA, USA), the report provides a global analysis of the patients, procedures, technologies, and companies driving growth and innovation in the POC testing market. More...
It is divided into three main segments: hospital bedside testing products; home and self-testing products; and physician's office lab products.

Each of these areas is divided by product and geography with detailed share-by-supplier information. Various factors contributing to the expected growth include: the demands of physicians for more efficient approaches to the delivery of care; demands for faster access to diagnostic test results to optimize patient outcomes in emergency and critical care settings; the development of advanced analytical technologies, including high-sensitivity assays suitable for POC use, as well as microfluidics technologies that enable highly sophisticated assays to be performed at the bedside by nonlaboratory personnel, with accuracy equivalent to that achieved in the central laboratory; and advanced computer and communications technologies that allow POC testing to be managed as effectively as tests performed in the central lab.

The report is based on a study that included more than 200 interviews with pathologists and laboratory directors; investigators and technical experts; and company presidents, marketing executives, and business development executives.

LSI delivers market data and competitive intelligence to medical technology executives, entrepreneurs, and investors. LSI produces the EMT (Emerging Medical Technologies) Database, EMT (Emerging Medical Technologies) Spotlight events, medtech market reports, and provides global custom research services.

Related Links:

Life Science Intelligence




Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Immunofluorescence Analyzer
IFA System
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.